|
Workshop
[In-Person] Clinical Pharmacology Across the Drug Development Continuum: Key Clinical Studies, Modeling & Simulation to Support Drug Approval and Labeling
Speakers:
Luzelena Caro (Gilead), Yuan Zhao (EMD Serono), Neha Bhis (Allucent), Joy Hsu (Genentech), Rajanikanth Madabushi (FDA)
Organizers:
Jennifer Dong (EMD Serono), Lisa Benincosa (Allucent), Ashley Lennox (Allucent), Manushree Bharadwaj (Allucent), Snow Ge (BridgeBio Pharma), Shichang Miao (Consultant)
Date:
2023-11-13
Time:
8:45-17:30 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs/Between Jobs: $125; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $995; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(5)Allucent; Altasciences; Emery Pharma; Meadowhawk Biolabs; PharmaBlock
Registration: http://www.PBSS.org
Registration deadline:2023-11-12
(it will close sooner if the seating cap is reached)
About the Topic
Clinical pharmacology is an integral component of drug development that plays a vital role in establishing the right target, right dose, and right population throughout the development and the life cycle management of an investigational product. This workshop will provide an overview of how clinical pharmacology contributes to key decision‑making milestones throughout the drug development process, from establishing a first-in-human dose to crafting the package insert for filing. The fundamental principles and strategy for conducting clinical pharmacology studies as well as modeling and simulation approaches to accelerate the drug development process will be covered. Real-world applications will illustrate contemporary approaches to developing and executing a clinical pharmacology program. This workshop is suitable for novice drug developers, experts from other disciplines interested in learning more about the field, and clinical pharmacologists looking to refresh their knowledge and discuss emerging topics.
Time (PT)
|
Topic
|
Presenter
|
8:45-9:05 am
|
PBSS Welcome and Introduction
|
Snow Ge, BridgeBio Pharma
|
9:05-10:20 am
|
The Role of Clinical Pharmacology in Drug Development
|
Luzelena Caro, PhD, Senior Director, Clinical Pharmacology, Gilead
|
10:20-10:30 am
|
Major Sponsor Presentation
|
Quotient Sciences
|
10:30-10:50 am
|
Break and Vendor Show
|
-
|
10:50-11:50 pm
|
Clinical Pharmacology Studies to Support Filing Packages and Labeling
|
Neha Bhise, PhD, Sr. Clinical Pharmacologist, Allucent
|
11:50-12:50 pm
|
Lunch
|
-
|
12:50-2:00 pm
|
Clinical Pharmacologic Evaluation of Population Variability in Global Drug Development
|
Yuan Zhao MS, PhD, Scientific Director, EMD Serono
|
2:00-3:00 pm
|
Application of Model-Informed Drug Discovery and Development in the Pharmaceutical Field
|
Joy Hsu, MS, PhD, Distinguished Scientist, Clinical Pharmacology, Genentech
|
3:00-3:10 pm
|
Major Sponsor Presentation
|
Fortrea
|
3:10-3:35 pm
|
Break
|
-
|
3:35-4:20 pm
|
Clinical Pharmacology Considerations in Regulatory Evaluation
|
Raj Madabushi, PhD, Associate Director, Guidance and Scientific Policy, Office of Clinical Pharmacology, OTS/CDER/FDA
|
4:20-4:50 pm
|
Panel Discussion
|
All Speakers
|
4:50-5:50 pm
|
Happy Hour
|
Sponsor, Alturas Analytics
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-08-14, [Free Online] Advances in Cancer Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro Delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|